Brussels, 16/11/2005 (Agence Europe) - The regulation of products created by cellular and tissue engineering were the missing piece of the jigsaw of the European market for medicines and products with therapeutic end-uses after the revision of European pharmaceutical legislation. The result of this was considerable disparities between the national markets, in terms of classification (certain products were considered as medicines in one Member State and as medical devices in others), of...